[{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Zai Lab","pharmaFlowCategory":"D","amount":"$187.0 million","upfrontCash":"$35.0 million","newsHeadline":"Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Collaboration","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.19,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.19,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Zai Lab Limited","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Zai Lab Limited"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic receptor","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Segal Trials","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Segal Trials","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Segal Trials"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Xanomeline","moa":"Muscarinic M1\/M4 receptor","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Karuna Therapeutics Announces Pricing of Public Offering of Common Stock","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.40000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"$100.0 million","newsHeadline":"PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.5,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.5,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$460.0 million","upfrontCash":"Undisclosed","newsHeadline":"Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Public Offering","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0.46000000000000002,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0.46000000000000002,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Goldman Sachs & Co. LLC"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"PureTech Health","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PureTech Health \/ Karuna Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PureTech Health \/ Karuna Therapeutics"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$14,000.0 million","upfrontCash":"$14,000.0 million","newsHeadline":"Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Acquisition","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$14,000.0 million","upfrontCash":"$14,000.0 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Acquisition","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":14,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":14,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Karuna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Karuna Therapeutics","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Karuna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Karuna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Xanomeline","moa":"","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Bristol Myers Squibb","amount2":0,"therapeuticAreaNew":"Psychiatry\/Psychology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bristol Myers Squibb \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bristol Myers Squibb \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for xanomeline tartrate
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
